Standard BioTools Adds Treeline Valuation Details To Address 15 Shareholder Demand Letters
The company denied the disclosure allegations as shareholders prepare to vote Thursday on the proposed Treeline merger.
Standard BioTools, which supplies tools for biomedical research, added Treeline merger information Monday to address 15 demand letters and two shareholder lawsuits, according to its SEC filing. The company maintained that its voting materials already met legal requirements, with shareholders scheduled to vote Thursday.
Disclosure Claims Reach New York Court
Standard BioTools said the voluntary additions were intended to resolve the disclosure claims and avoid litigation costs and delays to its business. The company denied the allegations and said it intends to defend against the letters and lawsuits.
The company received the demand letters between July 27 and November 9, 2026. One sought access to company books and records under Delaware law; the letters generally alleged that the merger materials omitted information investors needed.
The two complaints, Carroll v. Standard BioTools and Miller v. Standard BioTools, were filed on October 29 and October 30, respectively, in New York state court in New York County. They named the company and its directors and alleged that the merger voting materials omitted material information.
Two Advisers, Different Treeline Ranges
The additional information explains how financial advisers assessed Treeline's value using projected cash flows, a method that translates expected future cash into present-day value.
Centerview, Standard BioTools' financial adviser, estimated Treeline's implied value at $15.88 to $21.89 per share. UBS, which advised Standard BioTools' special committee, arrived at $13.59 to $17.07 per share in its separate analysis.
Both analyses valued forecast cash flows running from July 1, 2026, through December 31, 2050, as of June 30, 2026. Centerview used discount rates of 12% to 15%; UBS used 15% to 17%.
Centerview included approximately $510 million in estimated Treeline cash, estimated savings from tax losses and the projected net effect of future fundraising, including dilution. UBS included approximately $510 million in projected cash and approximately $43 million from the exercise prices of Treeline securities. Its fully diluted equity valuation ranged from about $2.6 billion to $3.3 billion.
The $468 Million Liquidation Estimate
Centerview also reviewed management's estimate of what Standard BioTools shareholders could receive in a liquidation. The analysis implied approximately $468 million in equity value at the time of distribution, or $1.14 per share after accounting for fully diluted shares.
Standard BioTools agreed on June 6, 2026, to merge with Treeline, which would survive as its wholly owned subsidiary. Treeline develops drug candidates.
Standard BioTools supplies instruments, consumables and services researchers use to examine proteins and genes while developing therapeutics. Its research-only platforms include CyTOF for single-cell analysis, Hyperion for mapping proteins in tissue and Biomark for genomics testing. Customers include academic institutions, cancer centers, clinical research laboratories and biotechnology and biopharmaceutical companies.
Standard BioTools shareholders are scheduled to vote on the proposed Treeline merger Thursday.
Sources
- 8-K Filing — STANDARD BIOTOOLS INC. (LAB) — SEC EDGAR